Liên Minh Châu Âu - Tiếng Ý - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - omeostasi del calcio - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Liên Minh Châu Âu - Tiếng Thụy Điển - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatid - osteoporosis; osteoporosis, postmenopausal - calciumhomeostas - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Liên Minh Châu Âu - Tiếng Malt - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - homeostasi tal-kalċju - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Ý - Tiếng Ý - AIFA (Agenzia Italiana del Farmaco)

sun pharmaceutical industries (europe) b.v. - paracalcitolo - paracalcitolo

Liên Minh Châu Âu - Tiếng Hà Lan - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - calcium homeostase - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Bồ Đào Nha - Tiếng Bồ Đào Nha - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

noridem enterprises limited - parecoxib - pó e solvente para solução injetável - 40 mg/2 ml - parecoxib sódico 42.36 mg - parecoxib - genérico - duração do tratamento: curta ou média duração

Bồ Đào Nha - Tiếng Bồ Đào Nha - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

noridem enterprises limited - parecoxib - pó e solvente para solução injetável - 40 mg/2 ml - parecoxib sódico 42.36 mg - parecoxib - genérico - duração do tratamento: curta ou média duração

Síp - Tiếng Hy Lạp - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

remedica ltd (0000003171) aharnon str., lemesos, 3056 - paracetamol - tablets - 500mg - paracetamol (0000103902) 500mg - paracetamol

Đức - Tiếng Đức - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

leo pharma a/s beiname: leo pharmaceutical products ltd. a/s (3180623) - heparin-natrium ((mit angaben zur herkunft)) - injektionslösung - teil 1 - injektionslösung; heparin-natrium ((mit angaben zur herkunft)) (01165) 5000 internationale einheit

Liên Minh Châu Âu - Tiếng Hy Lạp - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - Ομοιοστασία ασβεστίου - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.